title: Effects of nicotine on thromboxane/prostacyclin balance in myocardial ischemia.
abstract: It has been proven that nicotine contributes to cardiovascular diseases, although its precise mechanism of action is still unclear. The purpose of this study is to find how nicotine may complicate myocardial ischemia by affecting the thromboxane/prostacyclin (TXA(2)/PGI(2)) balance. We used four groups (n=7 each) of isolated and perfused rabbit hearts according to Langendorff method: (i) control group; (ii) group submitted to 1 microM nicotine perfusion during 60 min; (iii) group submitted to a regional ischemia by ligation of the left descending coronary artery during 60 min and (iv) group submitted to nicotine perfusion during ischemia. Levels of TXB(2) and 6-keto PGF(1alpha), the stable metabolites of TXA(2) and PGI(2) were then determined in the microsomes of the hearts by radioimmunoassay. The results showed that (1) a TXA(2) synthetase activity is present in the myocardium, and this activity, as well as that of PGI(2) synthetase, is decreased by a 60min ischemia; (2) TXA(2) and PGI(2) activities are not affected by nicotine in the normal myocardium and (3) nicotine infusion during ischemia contributes to the increase of TXA(2)/PGI(2) ratio further by decreasing PGI(2). Therefore, these results provide one explanation on how nicotine might worsen myocardial ischemia.
authors.affiliation: Laboratory of Physiology, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
authors.forename: R
authors.initials: R
authors.lastname: Nemr
authors.forename: B
authors.initials: B
authors.lastname: Lasserre
authors.forename: R
authors.initials: R
authors.lastname: Chahine
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000818:Animals; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System; D004791:Enzyme Inhibitors / Q000633:toxicity; D011464:Epoprostenol / Q000378:metabolism*; D006321:Heart / Q000187:drug effects; D066298:In Vitro Techniques; D019746:Intramolecular Oxidoreductases / Q000037:antagonists & inhibitors; D008297:Male; D008861:Microsomes / Q000187:drug effects / Q000378:metabolism; D017202:Myocardial Ischemia / Q000209:etiology* / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism; D009538:Nicotine / Q000633:toxicity*; D010477:Perfusion; D011817:Rabbits; D012907:Smoking / Q000009:adverse effects / Q000378:metabolism; D013928:Thromboxane A2 / Q000378:metabolism*; D013929:Thromboxane B2 / Q000378:metabolism
chemical_list: D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D013929:Thromboxane B2; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; D009538:Nicotine; D003577:Cytochrome P-450 Enzyme System; D011464:Epoprostenol; D019746:Intramolecular Oxidoreductases; C022461:prostacyclin synthetase